Serenex

Serenex is an integrated oncology-focused drug discovery and development company. Our mission is to improve the lives of cancer patients by developing proprietary therapeutic and supportive care products. Our most advanced program, SNX-1012, is a product for chemotherapy and radiation-induced oral mucositis. This is scheduled to complete Phase 2 trials in Q1 2007. Our most advanced preclinical-stage program, SNX-5422, is a novel small molecule inhibitor of Heat Shock Protein 90. Hsp90 is a chaperone protein for a variety of oncogenic proteins (such as Her2 and Raf) and their downstream signaling molecules (such as Akt and Erk). SNX-5542 is scheduled to begin clinical trials in Q1 2007.

Contact Details: 323 Foster Street Durham North Carolina 27701 United States of America Tel: (919) 281 6001 Fax: (919) 281 6050 Email: info@serenex.com WWW: www.serenex.com/

Loading...

Recent Publications by Serenex:
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. A novel class of heat shock protein 90 (Hsp90) inhibitors was developed...	26th August, 2009	Serenex Inc, Durham,	J Med Chem. 2009 Jul 23;52(14):4288-305. DOI Direct Link
Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. OBJECTIVE: To evaluate the ability of SNX-7081, a novel small molecule...	20th February, 2009	Serenex Inc., Durham, North Carolina 27701, USA.	Arthritis Rheum. 2008 Dec;58(12):3765-75. DOI Direct Link
Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Hsp90 maintains the conformational stability of multiple proteins...	30th August, 2008	Serenex, Inc., 323 Foster St., Durham, NC 27701, USA.	Bioorg Med Chem Lett. 2008 Jun 15;18(12):3517-21. Epub 2008 May 9. DOI Direct Link
Chemoproteomics-driven drug discovery: addressing high attrition rates. The advent of multiple high-throughput technologies has brought drug...	28th October, 2006	Serenex, 323 Foster	Drug Discov Today. 2006 Jun;11(11-12):495-502. DOI Direct Link
The use of high-content screening for the discovery and characterization of compounds that modulate mitotic index and cell cycle progression by differing mechanisms of action. The advent of high-content screening has expanded the ability of...	25th August, 2006	Serenex, Inc., Durham, NC 27701, USA.	Assay Drug Dev Technol. 2006 Apr;4(2):153-63. DOI Direct Link
→View more Serenex research publications.

Serenex Patents:
US Patent No.	Title
7371852	Alkyl-linked nucleotide compositions
7358370	Benzene, pyridine, and pyridazine derivatives
7282506	2,8-disubstituted naphthyridine derivatives
6716395	Integrated protein affinity capture centrifugation device

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 798 times since April 2007, the link to the organisation's website has been followed 145 times

Recent Search Terms used to find this page: serenex | serenex | Serenex | serenex durham nc | serenex | serenex | serenex, durham,nc | serenex | serenex | serenex durham nc | .

Search for more companies in Durham

Search for more companies in North Carolina

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Serenex